In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first FDA ...

CRISPR Therapeutics already has financial backing from Celgene and in October announced a discovery alliance with Vertex in cystic fibrosis. Novartis has a stake in rivals Intellia Therapeutics ...

ERS Genomics ('ERS'), which was established to provide broad access to the foundational CRISPR/Cas9 intellectual property ...

The CRISPR Technology Market is experiencing tremendous growth due to development in gene editing, rising applications in drug discovery, and growing agricultural biotechnology. Investment in ...

CRISPR technology, driven by Cas9, redefines gene editing, facilitating targeted DNA modifications that advance genetic ...

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing.

Dr. Francis Collins, a renowned geneticist, and former longtime director of the National Institutes of Health, is retiring ...

A pipeline for the analysis of CRISPR edited data. It allows the evaluation of the quality of gene editing experiments using targeted next generation sequencing (NGS) data (`targeted`) as well as the ...

The future of medicine with CRISPR and CAR-T therapy, exploring ethical, societal, and accessibility challenges in healthcare ...